NCT01667432View on ClinicalTrials.gov

An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B

CompletedOBSERVATIONAL
Enrollment

141

Participants

Timeline

Start Date

July 8, 2011

Primary Completion Date

August 12, 2014

Study Completion Date

August 12, 2014

Conditions
Hepatitis B, Chronic
Interventions
BIOLOGICAL

Peginterferon alfa-2a

Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.

Trial Locations (9)

1407

MHAT Tokuda Hospital Sofia; Department of Gastroenterology at Clinic of Internal Deseases, Sofia

1431

UMHAT Alexandrovska EAD; Gastroenterology, Sofia

1527

Mhat Queenjoanna; Clinic of Gastroenterology, Sofia

1606

Military Medical Academy; Gastroenterology, Sofia

1612

Mhat St. Ivan Rilski; Clinic of Gastroenterology, Sofia

4002

Umhat St. Georgi; Clinical of Gastroenterology, Plovdiv

5800

Mhat - Pleven; Clinic of Gastroenterology, Pleven

6000

Mhat St. Zagora; Clinical of Gastroenterology, Stara Zagora

9010

Mhat Sveta Marina; Clinic of Gastroenterology, Varna

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01667432 - An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B | Biotech Hunter | Biotech Hunter